GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » 3-Year Dividend Growth Rate

Acrux (ASX:ACR) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Acrux 3-Year Dividend Growth Rate?

Acrux's Dividends per Share for the six months ended in Dec. 2023 was A$0.00.

The historical rank and industry rank for Acrux's 3-Year Dividend Growth Rate or its related term are showing as below:

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Acrux was -9.10% per year. The lowest was -9.10% per year. And the median was -9.10% per year.

ASX:ACR's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 14.5
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Acrux's Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00. As of today, Acrux's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Acrux's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Acrux's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acrux's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrux's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Acrux's 3-Year Dividend Growth Rate falls into.



Acrux 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Acrux  (ASX:ACR) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Acrux's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=0/ -0.011
=N/A

During the past 13 years, the highest Dividend Payout Ratio of Acrux was 1.19. The lowest was 0.48. And the median was 0.77.

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

During the past 13 years, the highest Dividend Yield of Acrux was 26.09%. The lowest was 2.16%. And the median was 9.20%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acrux 3-Year Dividend Growth Rate Related Terms>


Acrux (ASX:ACR) Business Description

Industry
Traded in Other Exchanges
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.